We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience, read our Cookie Policy

Advertisement

SGX Collaborates with Novartis to Develop and Commercialize BCR-ABL Inhibitors

News   Mar 29, 2006

 
SGX Collaborates with Novartis to Develop and Commercialize BCR-ABL Inhibitors
 
 
Advertisement
 

RELATED ARTICLES

Synthesizing Bacteria-Killing Molecules From Wasp Venom

News

A team of researchers has engineered powerful new antimicrobial molecules from toxic proteins originally found in wasp venom.

READ MORE

Ultrapotent Compound Could Help Combat C. difficile

News

Scientists from Purdue University have advanced novel compounds that they have designed to help treat patients with Clostridioides difficile.

READ MORE

A Look at How Psychedelics Bind to Serotonin Receptors

News

For the first time, scientists have solved the high-resolution structure of psychedelic compounds when they are actively bound to the 5-HT2A serotonin receptor on the surface of brain cells.

READ MORE

 

To personalize the content you see on Technology Networks homepage, Log In or Subscribe for Free

LOGIN SUBSCRIBE FOR FREE